Beyond regulatory T cells: The potential role for IL-2 to deplete T-follicular helper cells and treat autoimmune diseases

Immunotherapy

Volumn 6, Issue 11, 2014, Pages 1207-1220

  Ballesteros Tato, André ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

autoimmune disease; germinal center B cells; IL 2; immunotherapy; T follicular helper cells; Tregs

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR;

AUTOIMMUNE DISEASE; CELL MATURATION; DRUG MECHANISM; HELPER CELL; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOTHERAPY; LOW DRUG DOSE; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T CELL DEPLETION; T LYMPHOCYTE SUBPOPULATION; ANIMAL; AUTOIMMUNE DISEASES; HUMORAL IMMUNITY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE DEPLETION; MOUSE; PROCEDURES;

ANIMALS; AUTOIMMUNE DISEASES; HUMANS; IMMUNITY, HUMORAL; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSION; IMMUNOTHERAPY; INTERLEUKIN-2; LYMPHOCYTE DEPLETION; MICE; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY;

EID: 84919791273     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.83     Document Type: Review

References (160)

1. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193(4257), 1007-1008 (1976
2. Wagner H, Hardt C, Heeg K, Rollinghoff M, Pfizenmaier K. T-cell-derived helper factor allows in vivo induction of cytotoxic T cells in nu/nu mice. Nature 284(5753), 278-278 (1980
3. Henney CS, Kuribayashi K, Kern DE, Gillis S. Interleukin-2 augments natural killer cell activity. Nature 291(5813), 335-338 (1981
4. Rosenberg SA. Raising the bar: The curative potential of human cancer immunotherapy. Sci. Transl. Med. 4(127), 127ps128 (2012
5. Pett SL, Kelleher AD, Emery S. Role of interleukin-2 in patients with HIV infection. Drugs 70(9), 1115-1130 (2010
6. Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 364(22), 2119-2127 (2011
7. Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl Cancer Inst. 86(15), 1159-1166 (1994
8. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17(13), 4550-4557 (2011
9. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-Tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-Tolerance causes various autoimmune diseases. J. Immunol. 155(3), 1151-1164 (1995
10. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: Mechanisms of differentiation and function. Annu. Rev. Immunol. 30, 531-564 (2012
11. Williams MA, Tyznik AJ, Bevan MJ. Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature 441(7095), 890-893 (2006
12. Pipkin ME, Sacks JA, Cruz-Guilloty F, Lichtenheld MG, Bevan MJ, Rao A. Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity 32(1), 79-90 (2010
13. Kalia V, Sarkar S, Subramaniam S, Haining WN, Smith KA, Ahmed R. Prolonged interleukin-2Ralpha expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo. Immunity 32(1), 91-103 (2010
14. Lenardo MJ. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature 353(6347), 858-861 (1991
15. Liao W, Lin JX, Leonard WJ. IL-2 family cytokines: New insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr. Opin. Immunol. 23(5), 598-604 (2011
16. Laurence A, Tato CM, Davidson TS, et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26(3), 371-381 (2007
17. Ballesteros-Tato A, Leon B, Graf BA, et al. Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation. Immunity 36(5), 847-856 (2012
18. Oestreich KJ, Mohn SE, Weinmann AS. Molecular mechanisms that control the expression and activity of Bcl- 6 in TH1 cells to regulate flexibility with a TFH-like gene profile. Nat. Immunol. 13(4), 405-411 (2012
19. Johnston RJ, Choi YS, Diamond JA, Yang JA, Crotty S. STAT5 is a potent negative regulator of TFH cell differentiation. J. Exp. Med. 209(2), 243-250 (2012
20. Nurieva RI, Podd A, Chen Y, et al. STAT5 protein negatively regulates T follicular helper (Tfh) cell generation and function. J. Biol. Chem. 287(14), 11234-11239 (2012
21. Leon B, Bradley JE, Lund FE, Randall TD, Ballesteros- Tato A. FoxP3+ regulatory T cells promote influenza-specific Tf h responses by controlling IL-2 availability. Nat. Commun. 5, 3495 (2014
22. Crotty S. Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 29, 621-663 (2011
23. Suzuki H, Duncan GS, Takimoto H, Mak TW. Abnormal development of intestinal intraepithelial lymphocytes and peripheral natural killer cells in mice lacking the IL-2 receptor beta chain. J. Exp. Med. 185(3), 499-505 (1997
24. Sadlack B, Lohler J, Schorle H, et al. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur. J. Immunol. 25(11), 3053-3059 (1995
25. Suzuki H, Kundig TM, Furlonger C, et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science 268(5216), 1472-1476 (1995
26. Sharfe N, Dadi HK, Shahar M, Roifman CM. Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor. Proc. Natl Acad. Sci. USA 94(7), 3168-3171 (1997
27. Caudy AA, Reddy ST, Chatila T, Atkinson JP, Verbsky JW. CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J. Allergy Clin. Immunol. 119(2), 482-487 (2007
28. Roifman CM. Human IL-2 receptor alpha chain Deficiency. Pediatr. Res. 48(1), 6-11 (2000
29. Cheng G, Yu A, Dee MJ, Malek TR. IL-2R signaling is essential for functional maturation of regulatory T cells during thymic development. J. Immunol. 190(4), 1567-1575 (2013
30. Yuan X, Cheng G, Malek TR. The importance of regulatory T-cell heterogeneity in maintaining self-Tolerance. Immunol. Rev. 259(1), 103-114 (2014
31. Saadoun D, Rosenzwajg M, Joly F, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N. Engl. J. Med. 365(22), 2067-2077 (2011
32. Matsuoka K, Koreth J, Kim HT, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci. Transl. Med. 5(179), 179ra143 (2013
33. Hartemann A, Bensimon G, Payan CA, et al. Low-dose interleukin 2 in patients with type 1 diabetes: A Phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 1(4), 295-305 (2013
34. Kennedy-Nasser AA, Ku S, Castillo-Caro P, et al. Ultra Low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin. Cancer Res. 20(8), 2215-2225 (2014
35. Baeyens A, Perol L, Fourcade G, et al. Limitations of IL-2 and rapamycin in immunotherapy of type 1 diabetes. Diabetes 62(9), 3120-3131 (2013
36. Malek TR. The biology of interleukin-2. Annu. Rev. Immunol. 26, 453-479 (2008
37. Zelante T, Fric J, Wong AY, Ricciardi-Castagnoli P. Interleukin-2 production by dendritic cells and its immuno-regulatory functions. Front. Immunol. 3, 161 (2012
38. Harris DP, Haynes L, Sayles PC, et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat. Immunol. 1(6), 475-482 (2000
39. Wang X, Rickert M, Garcia KC. Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors. Science 310(5751), 1159-1163 (2005
40. Rickert M, Wang X, Boulanger MJ, Goriatcheva N, Garcia KC. The structure of interleukin-2 complexed with its alpha receptor. Science 308(5727), 1477-1480 (2005
41. Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 38(1), 13-25 (2013
42. Brennan P, Babbage JW, Burgering BM, Groner B, Reif K, Cantrell DA. Phosphatidylinositol 3-kinase Couples the interleukin-2 Receptor to the Cell Cycle Regulator E2F. Immunity 7(5), 679-689 (1997
43. Walker SR, Nelson EA, Frank DA. STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas. Oncogene 26(2), 224-233 (2007
44. Fukao T, Koyasu S. Expression of functional IL-2 receptors on mature splenic dendritic cells. Eur. J. Immunol. 30(5), 1453-1457 (2000
45. Wuest SC, Edwan JH, Martin JF, et al. A role for interleukin-2 trans-presentation in Dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat. Med. 17(5), 604-609 (2011
46. Sabatos CA, Doh J, Chakravarti S, et al. A synaptic basis for paracrine interleukin-2 signaling during homotypic T cell interaction. Immunity 29(2), 238-248 (2008
47. Huse M, Lillemeier BF, Kuhns MS, Chen DS, Davis MM. T cells use two directionally distinct pathways for cytokine secretion. Nat. Immunol. 7(3), 247-255 (2006
48. Granucci F, Feau S, Angeli V, Trottein F, Ricciardi-Castagnoli P. Early IL-2 production by mouse dendritic cells is the result of microbial-induced priming. J. Immunol. 170(10), 5075-5081 (2003
49. Kulhankova K, Rouse T, Nasr ME, Field EH. Dendritic Cells Control CD4+CD25+ Treg Cell Suppressor Function in Vitro Through Juxtacrine Delivery of IL-2. PLoS ONE 7(9), e43609 (2012
50. Tokano Y, Murashima A, Takasaki Y, Hashimoto H, Okumura K, Hirose S. Relation between soluble interleukin 2 receptor and clinical findings in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 48(10), 803-809 (1989
51. Sawada S, Hashimoto H, Iijma S, et al. Increased soluble IL-2 receptor in serum of patients with systemic lupus erythematosus. Clin. Rheumatol. 12(2), 204-209 (1993
52. Ward MM, Dooley MA, Christenson VD, Pisetsky DS. The relationship between soluble interleukin 2 receptor levels and antidouble stranded DNA antibody levels in patients with systemic lupus erythematosus. J. Rheumatol. 18(2), 235-240 (1991
53. Ter Borg EJ, Horst G, Limburg PC, Kallenberg CG. Changes in plasma levels of interleukin-2 receptor in relation to disease exacerbations and levels of anti-dsDNA and complement in systemic lupus erythematosus. Clin. Exp. Immunol. 82(1), 21-26 (1990
54. Maier LM, Lowe CE, Cooper J, et al. IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production. PLoS Genet. 5(1), e1000322 (2009
55. Maier LM, Anderson DE, Severson CA, et al. Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J. Immunol. 182(3), 1541-1547 (2009
56. Russell SE, Moore AC, Fallon PG, Walsh PT. Soluble IL- 2Ralpha (sCD25) exacerbates autoimmunity and enhances the development of Th17 responses in mice. PLoS ONE 7(10), e47748 (2012
57. Bilate AM, Lafaille JJ. Induced CD4+Foxp3+ regulatory T cells in immune tolerance. Annu. Rev. Immunol. 30, 733-758 (2012
58. Abbas AK, Benoist C, Bluestone JA, et al. Regulatory T cells: Recommendations to simplify the nomenclature. Nat. Immunol. 14(4), 307-308 (2013
59. Bennett CL, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27(1), 20-21 (2001
60. Wildin RS, Ramsdell F, Peake J, et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat. Genet. 27(1), 18-20 (2001
61. Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 8(2), 191-197 (2007
62. Brunkow ME, Jeffery EW, Hjerrild KA, et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 27(1), 68-73 (2001
63. Malek TR, Yu A, Vincek V, Scibelli P, Kong L. CD4 regulatory T cells prevent lethal autoimmunity in IL- 2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity 17(2), 167-178 (2002
64. Lio CW, Hsieh CS. A two-step process for thymic regulatory T cell development. Immunity 28(1), 100-111 (2008
65. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 6(11), 1142-1151 (2005
66. D'Cruz LM, Klein L. Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat. Immunol. 6(11), 1152-1159 (2005
67. Bayer AL, Yu A, Malek TR. Function of the IL-2R for thymic and peripheral CD4+CD25+ Foxp3+ T regulatory cells. J. Immunol. 178(7), 4062-4071 (2007
68. Zheng SG, Wang J, Wang P, Gray JD, Horwitz DA. IL-2 is essential for TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J. Immunol. 178(4), 2018-2027 (2007
69. Davidson TS, Dipaolo RJ, Andersson J, Shevach EM. Cutting Edge: IL-2 is essential for TGF-beta-mediated induction of Foxp3+ T regulatory cells. J. Immunol. 178(7), 4022-4026 (2007
70. Burchill MA, Yang J, Vogtenhuber C, Blazar BR, Farrar MA. IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J. Immunol. 178(1), 280-290 (2007
71. Yao Z, Kanno Y, Kerenyi M, et al. Nonredundant roles for Stat5a/b in Directly regulating Foxp3. Blood 109(10), 4368-4375 (2007
72. Vang KB, Yang J, Mahmud SA, Burchill MA, Vegoe AL, Farrar MA. IL-2, -7, and -15, but not thymic stromal lymphopoeitin, redundantly govern CD4+Foxp3+ regulatory T cell development. J. Immunol. 181(5), 3285-3290 (2008
73. Bayer AL, Lee JY, De La Barrera A, Surh CD, Malek TR. A function for IL-7R for CD4+CD25+Foxp3+ T regulatory cells. J. Immunol. 181(1), 225-234 (2008
74. Furtado GC, Curotto De Lafaille MA, Kutchukhidze N, Lafaille JJ. Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J. Exp. Med. 196(6), 851-857 (2002
75. Yamanouchi J, Rainbow D, Serra P, et al. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat. Genet. 39(3), 329-337 (2007
76. Brand OJ, Lowe CE, Heward JM, et al. Association of the interleukin-2 receptor alpha (IL-2Ralpha)/CD25 gene region with Graves' disease using a multilocus test and tag SNPs. Clin. Endocrinol. 66(4), 508-512 (2007
77. Matesanz F, Fedetz M, Collado-Romero M, et al. Allelic expression and interleukin-2 polymorphisms in multiple sclerosis. J. NeuroImmunol. 119(1), 101-105 (2001
78. Genome-wide association study of 14, 000 cases of seven common Diseases and 3, 000 shared controls. Nature 447(7145), 661-678 (2007
79. Vella A, Cooper JD, Lowe CE, et al. Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms. Am. J. Hum. Genet. 76(5), 773-779 (2005
80. Lowe CE, Cooper JD, Brusko T, et al. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat. Genet. 39(9), 1074-1082 (2007
81. Hafler DA, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 357(9), 851-862 (2007
82. Lieberman LA, Tsokos GC. The IL-2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity. J. BioMed. Biotechnol. 2010, 740619 (2010
83. Hulme MA, Wasserfall CH, Atkinson MA, Brusko TM. Central role for interleukin-2 in type 1 diabetes. Diabetes 61(1), 14-22 (2012
84. Kitas GD, Salmon M, Farr M, Gaston JS, Bacon PA. Deficient interleukin 2 production in rheumatoid arthritis: Association with active disease and systemic complications. Clin. Exp. Immunol. 73(2), 242-249 (1988
85. Roncarolo MG, Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat. Rev. Immunol. 7(8), 585-598 (2007
86. Grinberg-Bleyer Y, Baeyens A, You S, et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J. Exp. Med. 207(9), 1871-1878 (2010
87. Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N. Engl. J. Med. 365(22), 2055-2066 (2011
88. Churlaud G, Jimenez V, Ruberte J, et al. Sustained stimulation and expansion of Tregs by IL2 control autoimmunity without impairing immune responses to infection, vaccination and cancer. Clin. Immunol. 151(2), 114-126 (2014
89. Humrich JY, Morbach H, Undeutsch R, et al. Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proc. Natl Acad. Sci. USA 107(1), 204-209 (2010
90. Tang Q, Henriksen KJ, Bi M, et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med. 199(11), 1455-1465 (2004
91. Tarbell KV, Yamazaki S, Olson K, Toy P, Steinman RM. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J. Exp. Med. 199(11), 1467-1477 (2004
92. Diaz-De-Durana Y, Lau J, Knee D, et al. IL-2 immunotherapy reveals potential for innate beta cell regeneration in the non-obese diabetic mouse model of autoimmune diabetes. PLoS ONE 8(10), e78483 (2013
93. Tang Q, Adams JY, Penaranda C, et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28(5), 687-697 (2008
94. Dendrou CA, Plagnol V, Fung E, et al. Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat. Genet. 41(9), 1011-1015 (2009
95. Garg G, Tyler JR, Yang JH, et al. Type 1 diabetes-Associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function. J. Immunol. 188(9), 4644-4653 (2012
96. Wofsy D, Dauphinee MJ, Kipper SB, Talal N. Interleukin-2 deficiency in murine systemic lupus erythematosus. Transact. Assoc. Am. Phys. 94, 341-348 (1981
97. Solomou EE, Juang YT, Gourley MF, Kammer GM, Tsokos GC. Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J. Immunol. 166(6), 4216-4222 (2001
98. Linker-Israeli M, Bakke AC, Kitridou RC, Gendler S, Gillis S, Horwitz DA. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J. Immunol. 130(6), 2651-2655 (1983
99. Rabinovitch A, Suarez-Pinzon WL, Shapiro AM, Rajotte RV, Power R. Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes 51(3), 638-645 (2002
100. Yu A, Zhu L, Altman NH, Malek TR. A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity 30(2), 204-217 (2009
101. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat. Immunol. 8(12), 1353-1362 (2007
102. Ito S, Bollard CM, Carlsten M, et al. Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers. Mol. Ther. 22(7), 1388-1395 (2014
103. Krieg C, Letourneau S, Pantaleo G, Boyman O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc. Natl Acad. Sci. USA 107(26), 11906-11911 (2010
104. Lee SY, Cho ML, Oh HJ, et al. Interleukin-2/anti-interleukin-2 monoclonal antibody immune complex suppresses collagen-induced arthritis in mice by fortifying interleukin-2/STAT5 signalling pathways. Immunol. 137(4), 305-316 (2012
105. Webster KE, Walters S, Kohler RE, et al. In vivo expansion of T reg cells with IL-2-mAb complexes: Induction of resistance to EAE and long-Term acceptance of islet allografts without immunosuppression. J. Exp. Med. 206(4), 751-760 (2009
106. Liu R, Zhou Q, La Cava A, Campagnolo DI, Van Kaer L, Shi FD. Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia. Eur. J. Immunol. 40(6), 1577-1589 (2010
107. Shapiro AM, Suarez-Pinzon WL, Power R, Rabinovitch A. Combination therapy with low dose sirolimus and tacrolimus is synergistic in preventing spontaneous and recurrent autoimmune diabetes in non-obese diabetic mice. Diabetologia 45(2), 224-230 (2002).
108. Walsh PT, Buckler JL, Zhang J, et al. PTEN inhibits IL-2 receptor-mediated expansion of CD4+ CD25+ Tregs. J. Clin. Invest. 116(9), 2521-2531 (2006
109. Long SA, Rieck M, Sanda S, et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function. Diabetes 61(9), 2340-2348 (2012
110. Ballesteros-Tato A, Randall TD. Priming of T follicular helper cells by dendritic cells. Immunol. Cell Biol. 92(1), 22-27 (2014
111. Yu D, Rao S, Tsai LM, et al. The transcriptional repressor Bcl-6 directs T follicular helper cell lineage commitment. Immunity 31(3), 457-468 (2009
112. Nurieva RI, Chung Y, Martinez GJ, et al. Bcl6 mediates the development of T follicular helper cells. Science 325(5943), 1001-1005 (2009
113. Johnston RJ, Poholek AC, Ditoro D, et al. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science 325(5943), 1006-1010 (2009
114. Goodnow CC, Vinuesa CG, Randall KL, Mackay F, Brink R. Control systems and decision making for antibody production. Nat. Immunol. 11(8), 681-688 (2010
115. Han S, Hathcock K, Zheng B, Kepler TB, Hodes R, Kelsoe G. Cellular interaction in germinal centers. Roles of CD40 ligand and B7-2 in established germinal centers. J. Immunol. 155(2), 556-567 (1995
116. Linterman MA, Beaton L, Yu D, et al. IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. J. Exp. Med. 207(2), 353-363 (2010
117. Vogelzang A, Mcguire HM, Yu D, Sprent J, Mackay CR, King C. A fundamental role for interleukin-21 in the generation of T follicular helper cells. Immunity 29(1), 127-137 (2008
118. Bryant VL, Ma CS, Avery DT, et al. Cytokine-mediated regulation of human B cell differentiation into Ig-secreting cells: Predominant role of IL-21 produced by CXCR5+ T follicular helper cells. J. Immunol. 179(12), 8180-8190 (2007
119. Allen CD, Okada T, Cyster JG. Germinal-center organization and cellular dynamics. Immunity 27(2), 190-202 (2007
120. Chang A, Henderson SG, Brandt D, et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J. Immunol. 186(3), 1849-1860 (2011
121. Pugh-Bernard AE, Silverman GJ, Cappione AJ, et al. Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance. J. Clin. Invest. 108(7), 1061-1070 (2001
122. Arce E, Jackson DG, Gill MA, Bennett LB, Banchereau J, Pascual V. Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus. J. Immunol. 167(4), 2361-2369 (2001
123. Grammer AC, Slota R, Fischer R, et al. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J. Clin. Invest. 112(10), 1506-1520 (2003
124. Weyand CM, Goronzy JJ. Ectopic germinal center formation in rheumatoid synovitis. Ann. NY Acad. Sci. 987, 140-149 (2003
125. Ding Y, Li J, Wu Q, et al. IL-17RA is essential for optimal localization of follicular Th cells in the germinal center light zone to promote autoantibody-producing B cells. J. Immunol. 191(4), 1614-1624 (2013
126. Luzina IG, Atamas SP, Storrer CE, et al. Spontaneous formation of germinal centers in autoimmune mice. J. leukocyte Biol. 70(4), 578-584 (2001
127. Wang JH, New JS, Xie S, et al. Extension of the germinal center stage of B cell development promotes autoantibodies in BXD2 mice. Arthritis Rheum. 65(10), 2703-2712 (2013
128. Kendall PL, Yu G, Woodward EJ, Thomas JW. Tertiary lymphoid structures in the pancreas promote selection of B lymphocytes in autoimmune diabetes. J. Immunol. 178(9), 5643-5651 (2007
129. Schroder AE, Greiner A, Seyfert C, Berek C. Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. Proc. Natl Acad. Sci. USA 93(1), 221-225 (1996
130. Baumjohann D, Preite S, Reboldi A, et al. Persistent antigen and germinal center B cells sustain T follicular helper cell responses and phenotype. Immunity 38(3), 596-605 (2013
131. Deenick EK, Chan A, Ma CS, et al. Follicular helper T cell differentiation requires continuous antigen presentation that is independent of unique B cell signaling. Immunity 33(2), 241-253 (2010
132. Leon B, Ballesteros-Tato A, Browning JL, Dunn R, Randall TD, Lund FE. Regulation of T(H)2 development by CXCR5+ dendritic cells and lymphotoxin-expressing B cells. Nat. Immunol. 13(7), 681-690 (2012
133. Angeli V, Ginhoux F, Llodra J, et al. B cell-driven lymphangiogenesis in inflamed lymph nodes enhances dendritic cell mobilization. Immunity 24(2), 203-215 (2006
134. Leon B, Ballesteros-Tato A, Misra RS, Wojciechowski W, Lund FE. Unraveling effector functions of B cells during infection: The hidden world beyond antibody production. Infect. Disord. Drug Targets 12(3), 213-221 (2012
135. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N. Engl. J. Med. 361(22), 2143-2152 (2009
136. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-To-severely active systemic lupus erythematosus: The randomized, double-blind, Phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62(1), 222-233 (2010
137. Merrill J, Buyon J, Furie R, et al. Assessment of flares in lupus patients enrolled in a Phase II/III study of rituximab (EXPLORER). Lupus 20(7), 709-716 (2011
138. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 64(4), 1215-1226 (2012
139. Sanz I, Lee FE. B cells as therapeutic targets in SLE. Nat. Rev. Rheumatol. 6(6), 326-337 (2010
140. Dilillo DJ, Hamaguchi Y, Ueda Y, et al. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion During CD20 immunotherapy in mice. J. Immunol. 180(1), 361-371 (2008
141. Ahuja A, Anderson SM, Khalil A, Shlomchik MJ. Maintenance of the plasma cell pool is independent of memory B cells. Proc. Natl Acad. Sci. USA 105(12), 4802-4807 (2008
142. Bekar KW, Owen T, Dunn R, et al. Prolonged effects of short-Term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis Rheum. 62(8), 2443-2457 (2010
143. Ma CS, Deenick EK. Human T follicular helper (Tfh) cells and disease. Immunol. Cell Biol. 92(1), 64-71 (2013
144. Tangye SG, Ma CS, Brink R, Deenick EK. The good, the bad and the ugly - TFH cells in human health and disease. Nat. Rev. Immunol. 13(6), 412-426 (2013
145. Simpson N, Gatenby PA, Wilson A, et al. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum. 62(1), 234-244 (2010
146. Luo C, Li Y, Liu W, et al. Expansion of circulating counterparts of follicular helper T cells in patients with myasthenia gravis. J. NeuroImmunol. 256(1-2), 55-61 (2013
147. Zhu C, Ma J, Liu Y, et al. Increased frequency of follicular helper T cells in patients with autoimmune thyroid disease. J. Clin. Endocrinol. Metabol. 97(3), 943-950 (2012
148. Liu R, Wu Q, Su D, et al. A regulatory effect of IL-21 on T follicular helper-like cell and B cell in rheumatoid arthritis. Arthritis Res. Ther. 14(6), R255 (2012
149. Ma J, Zhu C, Ma B, et al. Increased frequency of circulating follicular helper T cells in patients with rheumatoid arthritis. Clin. Dev. Immunol. 2012, 827480 (2012
150. Wang J, Shan Y, Jiang Z, et al. High frequencies of activated B cells and T follicular helper cells are correlated with disease activity in patients with new-onset rheumatoid arthritis. Clin. Exp. Immunol. 174(2), 212-220 (2013
151. Xu X, Shi Y, Cai Y, et al. Inhibition of increased circulating Tfh cell by anti-CD20 monoclonal antibody in patients with type 1 diabetes. PLoS ONE 8(11), e79858 (2013
152. He J, Tsai LM, Leong YA, et al. Circulating precursor CCR7(lo)PD-1(hi) CXCR5(+) CD4(+) T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure. Immunity 39(4), 770-781 (2013
153. Rankin AL, Guay H, Herber D, et al. IL-21 receptor is required for the systemic accumulation of activated B and T lymphocytes in MRL/MpJ-Fas(lpr/lpr)/J mice. J. Immunol. 188(4), 1656-1667 (2012
154. Bubier JA, Sproule TJ, Foreman O, et al. A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc. Natl Acad. Sci. USA 106(5), 1518-1523 (2009
155. Herber D, Brown TP, Liang S, Young DA, Collins M, Dunussi-Joannopoulos K. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R. Fc reduces disease progression. J. Immunol. 178(6), 3822-3830 (2007
156. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299(5609), 1033-1036 (2003
157. Choi YS, Eto D, Yang JA, Lao C, Crotty S. Cutting edge: STAT1 is required for IL-6-mediated Bcl6 induction for early follicular helper cell differentiation. J. Immunol. 190(7), 3049-3053 (2013
158. Harker JA, Lewis GM, Mack L, Zuniga EI. Late interleukin-6 escalates T follicular helper cell responses and controls a chronic viral infection. Science 334(6057), 825-829 (2011
159. Nakayamada S, Poholek AC, Lu KT, et al. Type I IFN induces binding of STAT1 to Bcl6: Divergent roles of STAT family transcription factors in the T follicular helper cell genetic program. J. Immunol. 192(5), 2156-2166 (2014
160. Nurieva RI, Chung Y, Hwang D, et al. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity 29(1), 138-149 (2008